Literature DB >> 16439127

Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: variations on the 1H-pyrimidin-2-one theme.

Hervé Geneste1, Wilhelm Amberg, Gisela Backfisch, Armin Beyerbach, Wilfried M Braje, Jürgen Delzer, Andreas Haupt, Charles W Hutchins, Linda L King, Daryl R Sauer, Liliane Unger, Wolfgang Wernet.   

Abstract

In our efforts to further pursue one of the most selective dopamine D(3)-receptor antagonists reported to date, we now describe the synthesis and SAR of novel and highly selective dopamine D(3) antagonists based on a 1H-pyridin-2-one or on a urea scaffold. The most potent compounds exhibited K(i) values toward the D(3) receptor in the nano- to subnanomolar range and high selectivity versus the related D(2) dopamine receptor. Thus, 1H-pyridin-2-one 7b displays oral bioavailability (F=37%) as well as brain penetration (brain plasma ratio 3.7) in rat. Within the urea series, an excellent D(3) versus D(2) selectivity (>100-fold) could be achieved by removal of one NH group (compound 6), although bioavailability (rat) was suboptimal (F<10%). These data significantly enhance our understanding of the D(3) pharmacophore and are expected to lead to novel approaches for the treatment of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439127     DOI: 10.1016/j.bmcl.2005.12.079

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior.

Authors:  Anne Stößel; Regine Brox; Nirupam Purkayastha; Harald Hübner; Carsten Hocke; Olaf Prante; Peter Gmeiner
Journal:  Bioorg Med Chem       Date:  2017-04-29       Impact factor: 3.641

2.  Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.

Authors:  Subramaniam Ananthan; Surendra K Saini; Guangyan Zhou; Judith V Hobrath; Indira Padmalayam; Ling Zhai; J Robert Bostwick; Tamara Antonio; Maarten E A Reith; Shea McDowell; Eunie Cho; Leah McAleer; Michelle Taylor; Robert R Luedtke
Journal:  J Med Chem       Date:  2014-08-15       Impact factor: 7.446

Review 3.  Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.

Authors:  Samuele Maramai; Sandra Gemma; Simone Brogi; Giuseppe Campiani; Stefania Butini; Holger Stark; Margherita Brindisi
Journal:  Front Neurosci       Date:  2016-10-05       Impact factor: 4.677

Review 4.  Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.

Authors:  Béla Kiss; István Laszlovszky; Balázs Krámos; András Visegrády; Amrita Bobok; György Lévay; Balázs Lendvai; Viktor Román
Journal:  Biomolecules       Date:  2021-01-14

5.  Fluorescent ligands for dopamine D2/D3 receptors.

Authors:  Anni Allikalt; Nirupam Purkayastha; Khajidmaa Flad; Maximilian F Schmidt; Alina Tabor; Peter Gmeiner; Harald Hübner; Dorothee Weikert
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

6.  Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders.

Authors:  Jan Kehr; Fu-Hua Wang; Fumio Ichinose; Shimako Yoshitake; Bence Farkas; Béla Kiss; Nika Adham
Journal:  Front Psychiatry       Date:  2022-01-12       Impact factor: 4.157

Review 7.  Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo.

Authors:  Béla Kiss; Balázs Krámos; István Laszlovszky
Journal:  Front Psychiatry       Date:  2022-03-24       Impact factor: 4.157

8.  Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.

Authors:  A Bhathena; Y Wang; J B Kraft; K B Idler; S J Abel; R R Holley-Shanks; W Z Robieson; B Spear; L Redden; D A Katz
Journal:  Transl Psychiatry       Date:  2013-04-09       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.